Oncolys BioPharma Inc. (TYO:4588)

Oncolys BioPharma Ratios and Metrics

Market cap in millions JPY. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 17, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	83,724	12,881	10,878	9,130	9,171	21,971
Market Cap Growth	331.21%	18.41%	19.14%	-0.44%	-58.26%	-19.57%
Enterprise Value	82,711	11,569	9,991	7,125	5,757	20,418
Last Close Price	2860.00	518.00	567.00	527.00	528.00	1503.00
PS Ratio	2932.94	410.43	172.56	9.35	14.27	69.93
PB Ratio	47.28	4.68	7.38	4.23	2.55	10.97
P/TBV Ratio	47.28	4.68	7.38	4.23	2.55	10.97
EV/Sales Ratio	-	368.62	158.50	7.30	8.96	64.99
Debt / Equity Ratio	0.19	0.12	0.21	0.18	0.14	0.26
Net Debt / Equity Ratio	-0.57	-0.76	-0.83	-0.61	-0.82	-0.77
Net Debt / EBITDA Ratio	0.50	1.24	0.63	1.08	1.95	0.92
Net Debt / FCF Ratio	-	1.03	0.91	0.77	1.69	1.05
Asset Turnover	0.01	0.01	0.03	0.28	0.18	0.09
Inventory Turnover	-	-	2.19	35.52	40.10	6.15
Quick Ratio	5.19	10.14	4.32	6.19	8.91	5.38
Current Ratio	6.62	12.28	5.17	8.11	9.76	6.13
Return on Equity (ROE)	-110.09%	-79.73%	-106.71%	-39.94%	-57.72%	-76.78%
Return on Assets (ROA)	-55.37%	-40.26%	-51.44%	-22.01%	-26.86%	-29.41%
Return on Invested Capital (ROIC)	-345.38%	-365.97%	-351.64%	-164.69%	-276.12%	-306.97%
Return on Capital Employed (ROCE)	-108.70%	-57.30%	-116.20%	-52.50%	-39.40%	-70.90%
Earnings Yield	-2.45%	-13.08%	-17.82%	-12.58%	-17.61%	-9.54%
FCF Yield	-	-15.71%	-12.34%	-18.82%	-19.01%	-6.68%
Buyback Yield / Dilution	-21.76%	-22.67%	-2.71%	-2.44%	-17.54%	-3.41%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.